Nanoparticles combined with cells, drugs, and specially designed genes provide improved therapeutic efficacy in studies and clinical setting, demonstrating a new era of treatment strategy, especially in retinal diseases. Nanotechnology-based drugs can provide an essential platform for sustaining, releasing and a specific targeting design to treat retinal diseases. Poly-lactic-co-glycolic acid is the most widely used biocompatible and biodegradable polymer approved by the Food and Drug Administration. Many studies have attempted to develop special devices for delivering small-molecule drugs, proteins, and other macromolecules consistently and slowly. In this article, we first review current progress in the treatment of age-related macular degeneration. Then, we discuss the function of vascular endothelial growth factor (VEGF) and the pharmacological effects of anti-VEGF-A antibodies and soluble or modified VEGF receptors. Lastly, we summarize the combination of antiangiogenic therapy and nanomedicines, and review current potential targeting therapy in age-related macular degeneration.
Introduction
Age-related macular degeneration (AMD) is a common degeneration of retina in aging people, characterized by a yellowish deposit in the macula in dry type and choroidal neovascularization (CNV) in wet type. Wet AMD, also named neovascular AMD, is the leading cause of visual impairment in the elderly in industrialized countries, and results in blurred central vision due to macular edema from vascular hyperpermeability and abnormal blood vessel growth behind the macula. 1 Vascular endothelial growth factor (VEGF), a protein essential in angiogenesis and vascular hyperpermeability, is highly associated with wet AMD. According to the severity of wet AMD, several treatment choices are available nowadays, including intravitreal injection of therapeutic agents, argon laser photocoagulation of abnormal vessels, photodynamic therapy with verteporfin, and vitreoretinal surgery as a final resolution. Argon laser photocoagulation has been used to directly destroy the abnormal CNV membrane since the 1970s, 2 playing an important role in the treatment of wet AMD before we knew the importance of VEGF. Photocoagulation is now used as a supplement to treat extrafoveal neovascularization and polypoidal choroidal vasculopathy, a variant of AMD, due to its tissue-destroying effect. Photodynamic therapy is targeted at the subfoveal CNV to prevent traditional laser burn in the macula. 3 It is performed with the assistance of an intravenously injected photosensitive agent, followed by exposure to light of a specific wavelength (689 nm). However, its clinical application is limited due to its high cost and possible choroidal ischemia after treatment. 4 Considering the pathophysiology of wet AMD, it is believed that the causes of neovascularization are increased intraocular concentration of VEGF and macrophage-induced inflammation within retinal tissues. Thus, intravitreal injection of anti-VEGF agents and/or anti-inflammatory drugs (mainly steroids) monthly for at least three times has become a consensus in the treatment of patients with fresh and recurrent wet AMD. 5 Since intraocular delivery of a steroid may lead to elevated intraocular pressure or cataract formation, this treatment should be used selectively, especially in young patients. 6 In patients with refractory wet AMD presenting severe vitreous hemorrhage and epiretinal CNV membrane, 7 vitreoretinal surgery should be considered to remove the blood and restore the integrity of the retinal structure.
2. VEGF, anti-VEGF-A antibodies, and soluble or modified VEGF receptors VEGF belongs to a growth factor family, which includes VEGF-A, VEGF-B, VEGF-C, VEGF-D, and placental growth factor. 8 VEGF-A induces hemangiogenesis through VEGF receptor-2 (VEGFR-2), and VEGF-C/VEGF-D stimulates lymphangiogenesis through VEGFR-2 and VEGFR-3. Currently, anti-VEGF agents such as bevacizumab (Avastin, Genentech, CA, USA), ranibizumab (Lucentis, Genentech, CA, USA), and aflibercept (Eylea, Regeneron Pharmaceuticals, NY, USA) are available in the market. Bevacizumab is a whole anti-VEGF-A immunoglobulin, while ranibizumab is a fab fragment of an antibody against VEGF-A. By contrast, aflibercept is a new recombinant fusion protein that is composed of two main components, the VEGF binding portions from the extracellular domains of human VEGFR-1 and VEGFR-2, which is then fused to the Fc portion of human immunoglobulin G1. 13 Aflibercept has the ability to bind VEGF-A, VEGF-B, or placental growth factor and to inhibit angiogenesis. Currently, many studies are comparing the efficacy and safety of these three drugs.
By contrast, studies have found a common expression of soluble VEGFRs on the corneal surface. These truncated forms of VEGFR are formed by alternative splicing or proteolytic shedding, and can block the effect of VEGF ligand by VEGF trapping, further preventing their binding at membranebound VEGFRs. This mechanism helps inhibit angiogenesis and further maintains avascularity of cornea. 14e18 The soluble truncated form of VEGFR-1 (Flt-1), called fms-like tyrosine kinase (sFlt-1, sVEGFR-1), has high affinity for VEGF-A. 14 VEGFR-2 and VEGFR-3 both have their soluble forms, sVEGFR-2 and sVEGFR-3, respectively, and can block the function of VEGF-C. 16, 18 VEGFR intraceptor can also block VEGF. Lys-Asp-GluLeu (KDEL) is a quadripeptide retention signal that binds endoplasmic reticulum retention receptors. Thus, proteins coupled with KDEL cannot be secreted from the endoplasmic reticulum. 19 When domains 2 and 3 of VEGFR-1 are coupled to KDEL, the recombinant construct can bind VEGF intracellularly and block the function of VEGF. Flt23k (coupled domains 2e3 of Flt-1 with KDEL) was found to be a potential therapeutic agent for CNV in primate and murine AMD models. 20 
Nanotechnology-based drug delivery treatment
Most of the developing intraocular therapies are aiming at the reduction of macular edema or suppression of CNV resulting from elevated vitreous VEGF under several conditions, including not only AMD, but also diabetic retinopathy and retinal venous occlusion. Recently, naturally biodegradable or synthetic nanoparticulated drug delivery systems have been proposed as promising and alternative drug carriers in the treatment of retinal diseases. Nanotechnology can create and combine materials or devices with drugs and specially designed genes at a size of < 100 nm and, with advantages such as slow release, better tissue penetration, and higher drug packing, can help monitor, control, and cure diseases. 21 Fig . 1 shows the current applications of nanotechnology in ocular diseases, and the following section presents the details of current development of intraocular therapy with the use of nanomedicines.
Intraocular therapy by intravitreal injection
Current nanotechnology-based applications in intraocular therapy are summarized in Table 1 and described as follows.
VEGF-associated products
Nowadays, patients with neovascular AMD can reach better visual outcomes by the administration of different types of VEGF antagonists. 22 However, these treatments require frequent injections on a long-term basis, which may lead to patient noncompliance and increased risks of iatrogenic injury, such as bleeding, retinal detachment, and even endophthalmitis. 23 Therefore, a formulation with a stable, efficient, yet sustained releasing profile is necessary for the development of future therapeutics against AMD.
Poly-lactic acid (PLA) and poly-lactic-co-glycolic acid (PLGA) are biocompatible and biodegradable polymers, which have been approved by the Food and Drug Administration for use in drug products and widely studied for delivery of therapeutic molecules, especially proteins and peptides. 24 PLGA can be hydrolyzed to form natural metabolites (lactic and glycolic acids) and is eliminated from the body. 25 A number of approaches have been investigated for the preparation of drug-encapsulated polymers in the form of microparticles and nanoparticles. 26, 27 The supercritical fluid technology is applicable for pharmaceutical manufacturing and generation of microparticle-based formulations for both small and large molecules. 28 While being above their critical point, supercritical fluids have fluid-like densities and gas-like diffusivity, which allow sufficient mixing under supercritical conditions. Yandrapu et al 29 prepared PLA nanoparticles in porous PLGA microparticles (NPinPMP) with bevacizumab using supercritical carbon dioxide. Supercritical carbon Fig. 1 . Nanoparticles can contain medication agents and plasmid vectors, or have a ligand coating on their surface. Applications of nanotechnology in ocular diseases are divided into five parts: (1) nanotechnology-based drug delivery systems have better permeation and longer retention; (2) nanotechnology-based therapies can supply better surface protection and better coverage; (3) nanoparticles can be used in gene therapy; plasmid vectors in nanoparticles were phagocytosed by cells, and the genes were further released; (4) ligand-coated nanoparticles have a homing effect and can be applied for target therapies; and (5) nanotechnology-based therapies can prevent drugs from rapid degradation and further reduce drug toxicity. 20 worked on targeted delivery of integrin-binding linear RGD (Arg-Gly-Asp) peptide against VEGF using PLGA nanoparticles with the aid of recombinant Flt23k intraceptor plasmid, which is capable of homing the delivery system to neovascular lesions in the retina and regressing CNV in both primate and murine AMD models. The delivery system showed no ocular and systemic toxicity. After intravenous injection, RGD-functionalized nanoparticles were shown to be localized at CNV lesions. More excitingly, restoration of vision function after treatment with RGD-Flt23k nanoparticles was validated in both primate and murine AMD models. Luo et al's 20 results are important in that RGDtargeted nanoparticles delivering Flt23k intraceptor plasmids provide a different approach for ocular orientation through systemic administration (intravenous injection). This treatment can abolish neovascularization and fibrosis in animal AMD models while preventing serious side effects related to intraocular injection of anti-VEGF agents.
Steroids
To reduce the side effects of intravitreal injection of steroids, Daull and colleagues 30 used a lipophilic prodrug of dexamethasone (DXM), dexamethasone palmitate (DXP), for treatment of macular edema in several animal models, including rats, rabbits, cats, and minipigs. They tried to characterize the sustained release capacity, efficacy, and safety of intravitreal injection of DXP emulsions in preclinical situations. The results showed good efficacy in both rat and rabbit models. In addition, the pharmacokinetic data of rabbit presented sustained DXM concentrations in the retina and choroid. The DXM concentrations were found to be sufficient to suppress VEGF-induced vascular hyperpermeability up to 9 months. Therefore, intravitreal injection of DXP emulsion was efficacious for a sustained drug release, and potentiated the control of vascular leakage for up to 9 months following only a single dose of intravitreal injection. Daull et al's 30 study demonstrated that intravitreal injection of DXP emulsion could be a safe and effective alternative drug delivery platform for corticosteroids against macular edema.
Ozurdex, an intravitreal DXM implant (Allergan Inc., Irvine, CA, USA), has been approved for the treatment of macular edema in branch retinal venous occlusion and central retinal venous occlusion. 31, 32 However, it is also regarded as an adjunct therapy for patients with wet AMD refractory to anti-VEGF agents. Calvo et al 33 found Ozurdex to be effective in vision stabilization, reduction of intra-and subretinal fluids, and improvement of central retinal thickness in eyes with refractory wet AMD. It is a slow-releasing DXM implant that is injected through the pars plana. This implant is composed of a biodegradable, PLGA-based (NOVADUR solid polymer delivery system) copolymer matrix, which helps control the release of DXM, and allows DXM to maintain a high concentration in the vitreous during the first 2 months after injection and at a lower concentration later for up to 6 months. 32, 34 Recently, Suen and Chau 35 developed triamcinolone acetonide (TA)-loaded, folate-modified poly (ethylene glycol)-bpolycaprolactone (folate-PEG-b-PCL) nanoparticles by nanoprecipitation. A sustained release of TA from the nanoparticles was achieved for up to 4 weeks at pH 5.5 and 8 weeks at pH 7.4. In the cell (ARPE-19 cells) uptake experiment, downregulation of VEGF and upregulation of pigment epitheliumderived factor, lasted for at least 3 weeks. This nanoparticlebased TA delivery system was highlighted as a possible replacement for the current intravitreal injection treatment. Furthermore, folate modification enhances the solubility of TA, while the encapsulation of TA reduces its possible cytotoxicity.
Other materials with antiangiogenic agents
Shmueli et al 36 discovered several classes of peptides with very strong antiangiogenic properties. In order to prevent peptide degradation, serpin-derived peptide was first selfassembled with positively charged poly (beta-amino ester), to form the nanoparticles. To further prolong the release, the manufactured polymerepeptide nanoparticles were then encapsulated into PLGA microparticles. The peptide-carrying microparticles showed nearly zero-order release of the peptide for up to 200 days. In addition, long-term in vivo studies in the laser-induced neovascularization rat model showed that these peptide-releasing microparticles suppressed angiogenesis for > 14 weeks in vivo after a single intravitreal injection, revealing that the combination of serpin-derived peptide and biodegradable polymer-based particles was likely to be a suitable tool for future long-term treatment of chronic ocular diseases, especially AMD.
Celecoxib is a cyclooxygenase-2 inhibitor, characterized by its anti-inflammatory, antiproliferative, and anti-VEGF effects on the retina. 37 Palamoor and Jablonski 38 prepared celecoxibloaded poly (ortho ester) nanoparticles for intraocular drug delivery against AMD and diabetic retinopathy, the two leading causes of blindness in the elder. Their nanoparticulated formulation showed a zero-order release due to surface erosion and no burst release of celecoxib. Moreover, in the cell-uptake study, the formulated nanoparticles were not internalized by Müller and HEK 293 cells, which implied that these nanoparticles could be a suitable platform for drug delivery specific to the posterior segment of the eyes against AMD.
Intraocular therapies by other routes
Although intraocular therapy with intravitreal injection directly delivers drug compounds to the posterior segment of the eye, potential side effects limit long-term therapy. 23 However, achieving therapeutic concentrations of drugs by conventional oral and intravenous routes is difficult because of the presence of ocular barriers. 39 Drug administration by subconjunctival route is less invasive and considered as an alternative to the intravitreal route, but such treatments require frequent intervention. 40 Subconjunctival administration of drugs with nanoparticles can be further dispersed in PLGAePEGePLGA thermosensitive gels to sustain the drug release. 39, 41 After injection, these thermogelling systems form a depot above the sclera and slowly release drugs for the treatment of diseases in the posterior segment. Boddu et al 39 prepared nanoparticulated gel formulations of steroids by oil-in-water emulsion and dialysis methods using PLGA 50:50 and PLGA 65:35. They found that the nanoparticles suspended in thermosensitive gels released steroids obeying zero-order kinetics without an apparent burst effect, and concluded that these novel systems could provide sustained retinal/choroidal delivery of a steroid following episcleral administration. Further studies are needed to evaluate the effects of other medications, such as anti-VEGF agents, in these thermosensitive nanoparticulate gel systems for creating a safer way to treat CNV in AMD.
Specific targeting therapy for AMD

Complement-associated specific targeting therapy
Since 2005, several studies have found that AMD is associated with a variation in the gene that encodes complement factor H (CFH), and in patients who have one copy of Y402H polymorphism, there is a nearly fivefold increase in the risk of having AMD. 42e45 It implies that dysregulation of the complement system has a role in the pathogenesis of AMD. The most well-known CFH genetic variant of AMD is the Y402H polymorphism (a tyrosine-to-histidine substitution at amino acid position 402 within the CFH protein). Besides CFH, other complement pathways encoding genes such as complement factor B, C2, C3, and I were also reported to be associated with the risk of AMD. 46 Therefore, molecular targeting of the complement pathways may help in the prevention and treatment of AMD. Currently, clinical trials of Potentia (C3 inhibitor), ARC1905 (C5 inhibitor), eculizumab (humanized monoclonal antibodies binding C5), Tanox (complement factor D inhibitor), and TA106 (complement factor B inhibitor) are in process. 47 C5a receptor antagonists, JSM-7717 and JPE-1375, are also currently in preclinical assessment. 47 Regarding CFH, Wyatt et al 48 used quantitative yeast twohybrid and enzyme-linked immunosorbent assays with different recombinant protein constructs, finding higher affinity of Fib3 for the disease-related CFH 402H variant. In two AMD tissue donors who were homozygous for CFH 402H (H/H), colocalization of CFH and Fib3 in globular deposits within soft drusen was also observed, which was distinct from those seen in eyes with Y/Y and H/Y genotypes. It was concluded that CFH 402H/Fib3 interaction could aggregate the development of soft drusen and could be a target for therapeutic intervention.
Interleukin-17
AMD is thought to be associated with the inflammatory response in the macula, where several inflammatory signals are involved, such as interleukin (IL). The IL-17 cytokine family contained six members named AeF, among which IL-17A is the main cytokine. IL-17A and IL-17 receptor (R)-C increase in AMD eyes and blood, implying IL-17 involvement in AMD pathogenesis. Targeting IL-17, IL-17R-C, or cells producing IL-17 may lessen retinal degeneration and could be considered as a potential therapeutic target for AMD. 49 
Apurinic endonuclease 1/redox factor-1
Inhibition of the redox function of apurinic endonuclease 1/ redox factor-1 (APE1/Ref-1) can suppress endothelial angiogenesis and promote neuronal cell recovery, and is regarded as a potential treatment for AMD. Li et al 50 found that a smallmolecule compound E3330, a specific inhibitor of APE1 redox function, can regulate retinal pigment epithelium (RPE) cell response to oxidative stress. E3330 can block sublethal doses of oxidized low-density lipoprotein, decrease the proliferation decline and aging of RPEs, and lessen intracellular reactive oxygen species, monocyte chemoattractant protein-1, VEGF, and nuclear factor-kB p65 in RPEs. An animal study also demonstrated that intravitreal injection of E3330 could effectively treat laser-induced CNV in mouse eyes.
Rap1 GTPase
Dysfunction of barrier of RPE contributes to one of the mechanisms of development of AMD. Regulation of endothelial and epithelial cell junctions is associated with Rap1 GTPase, which has two isoforms, Rap1A and Rap1B. Wittchen et al 51 used shRNA of Rap1 isoforms in cultured human RPE cells and knockout mouse models to test the role of Rap1 in RPE cells. They found that Rap1A and Rap1B are involved in steady-state barrier integrity and dynamic junctional responses of RPE cells, respectively. In the laser injury model, Rap1b(À/À) mice had larger CNV volumes, compared to wild-type or Rap1a(À/À) mice. Intravitreal injection of a Rap1 activator, a cAMP analog (8CPT-2 0 -O-Me-cAMP), could significantly reduce the CNV volume. They concluded that 8CPT-2 0 -O-Me-cAMP might be a potential treatment option for AMD.
In conclusion, to date, anti-VEGF drugs are the most widely used medications for neovascular AMD. However, there are still limitations in the clinical use of these drugs. Additionally, there is still no promising treatment for dry AMD. In recent years, nanotechnology-based drug delivery treatments for intraocular therapies of AMD have attracted a great deal of interests. PLA-and PLGA-based drug delivery systems are under investigation. We have summarized the recent developments of nanotechnology-based drug delivery treatments and specific targeting therapy of AMD in this article. We hope that one day these advancements will have great outcomes in treating this common and destructive retinal disorder.
